{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:21:03Z","timestamp":1785842463276,"version":"3.56.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"23","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,12,1]]},"DOI":"10.2146\/ajhp140041","type":"journal-article","created":{"date-parts":[[2014,11,17]],"date-time":"2014-11-17T22:57:21Z","timestamp":1416265041000},"page":"2029-2036","source":"Crossref","is-referenced-by-count":66,"title":["Effects of maternal bisphosphonate use on fetal and neonatal outcomes"],"prefix":"10.1093","volume":"71","author":[{"given":"Sarah B.","family":"Green","sequence":"first","affiliation":[{"name":"WakeMed Health and Hospitals, Raleigh, NC; at the time of writing she was Intern, Drug Information, Department of Pharmacy, University of North Carolina Hospitals (UNCH), Chapel Hill."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley L.","family":"Pappas","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, UNCH"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"2019041605211953200_b1-0712029","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice","volume":"83","author":"Drake","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"2019041605211953200_b2-0712029","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.beem.2008.07.001","article-title":"Bisphosphonates: how do they work?","volume":"22","author":"Papapoulos","year":"2008","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2019041605211953200_b3-0712029","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1136\/bmj.309.6956.711","article-title":"The therapeutic use of bisphosphonates","volume":"309","author":"Compston","year":"1994","journal-title":"BMJ"},{"key":"2019041605211953200_b4-0712029","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1089\/jwh.2008.0887","article-title":"Clinical characteristics and medication use among premenopausal women with osteoporosis and low BMD: the experience of an osteoporosis referral center","volume":"18","author":"Cohen","year":"2009","journal-title":"J Womens Health (Larchmt)"},{"key":"2019041605211953200_b5-0712029","first-page":"37","volume-title":"Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk","author":"Briggs","year":"2011","edition":"9th ed"},{"key":"2019041605211953200_b6-0712029","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/(SICI)1096-9926(199908)60:2<68::AID-TERA10>3.0.CO;2-H","article-title":"Trans-placental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats","volume":"60","author":"Patlas","year":"1999","journal-title":"Teratology"},{"key":"2019041605211953200_b7-0712029","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/bdra.10016","article-title":"No effects of bisphosphonates on the human fetus","volume":"67","author":"Rutgers-Verhange","year":"2003","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"2019041605211953200_b8-0712029","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00198-003-1399-y","article-title":"Pharmacovigilance study of alendronate in England","volume":"14","author":"Biswas","year":"2003","journal-title":"Osteoporos Int"},{"key":"2019041605211953200_b9-0712029","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.reprotox.2006.05.009","article-title":"The outcome of pregnancy following pre-pregnancy or early pregnancy alendronate treatment","volume":"22","author":"Ornoy","year":"2006","journal-title":"Reprod Toxicol"},{"key":"2019041605211953200_b10-0712029","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.reprotox.2005.04.007","article-title":"Intrauterine growth restriction\u2014etiology and consequences: what do we know about the human situation and experimental animal models?","volume":"20","author":"Ergaz","year":"2005","journal-title":"Reprod Toxicol"},{"key":"2019041605211953200_b11-0712029","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00198-009-0983-1","article-title":"Maternal and fetal outcome after long-term bisphosphonate exposure before conception","volume":"21","author":"Hassen-Zrour","year":"2010","journal-title":"Osteoporos Int"},{"key":"2019041605211953200_b12-0712029","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.tjog.2012.04.029","article-title":"Uncomplicated vaginal delivery in two consecutive pregnancies carried to term in a woman with osteogenesis imperfecta type I and bisphosphonate treatment before conception","volume":"51","author":"Chen","year":"2012","journal-title":"Taiwan J Obstet Gynecol"},{"key":"2019041605211953200_b13-0712029","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1136\/ard.49.11.955-a","article-title":"Antenatal administration of aminopropylidene diphosphonate","volume":"49","author":"Dunlop","year":"1990","journal-title":"Ann Rheum Dis"},{"key":"2019041605211953200_b14-0712029","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1097\/01.AOG.0000209183.39581.e9","article-title":"Malignant hypercalcemia in pregnancy: effect of pamidronate on uterine contractions","volume":"108","author":"Culbert","year":"2006","journal-title":"Obstet Gynecol"},{"key":"2019041605211953200_b15-0712029","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0936-6555(05)80667-3","article-title":"Malignant hypercalcaemia in pregnancy and antenatal administration of intravenous pamidronate","volume":"8","author":"Illidge","year":"1996","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"2019041605211953200_b16-0712029","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1210\/jc.2005-2548","article-title":"Maternal and infant outcome after pamidronate treatment of polyostotic fibrous dysplasia and osteogenesis imperfecta before conception: a report of four cases","volume":"91","author":"Chan","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041605211953200_b17-0712029","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00247-006-0153-y","article-title":"Pediatric DXA: technique and interpretation","volume":"37","author":"Binkovitz","year":"2007","journal-title":"Pediatr Radiol"},{"key":"2019041605211953200_b18-0712029","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1007\/s00198-009-1138-0","article-title":"Intravenous bisphosphonate treatment and pregnancy: its effects on mother and infant bone health","volume":"21","author":"Mastaglia","year":"2010","journal-title":"Osteoporos Int"},{"key":"2019041605211953200_b19-0712029","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1359\/JBMR.040711","article-title":"Maternal and fetal outcome after long-term pamidronate treatment before conception: a report of two cases","volume":"19","author":"Munns","year":"2004","journal-title":"J Bone Miner Res"},{"key":"2019041605211953200_b20-0712029","first-page":"344","article-title":"Maternal and fetal outcome of pamidronate treatment before conception: a case report","volume":"25","author":"Cabar","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"2019041605211953200_b21-0712029","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ygyno.2004.06.037","article-title":"Combined chemotherapy and radiotherapy during conception and first two trimesters of gestation in a woman with metastatic breast cancer","volume":"95","author":"Andreadis","year":"2004","journal-title":"Gynecol Oncol"},{"key":"2019041605211953200_b22-0712029","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s00296-011-1816-z","article-title":"Pregnancy\u2013associated spinal osteoporosis treated with bisphosphonates: long-term follow-up of maternal and infants outcome","volume":"32","author":"Vujasinovic-Stupar","year":"2012","journal-title":"Rheumatol Int"},{"key":"2019041605211953200_b23-0712029","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.bone.2008.11.001","article-title":"Pregnancy outcome following in utero exposure to bisphosphonates","volume":"44","author":"Levy","year":"2009","journal-title":"Bone"},{"key":"2019041605211953200_b24-0712029","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1007\/s12098-010-0176-0","article-title":"Hypocalcemia in the newborn","volume":"77","author":"Jain","year":"2010","journal-title":"Indian J Pediatr"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/71\/23\/2029\/28451000\/ajhp2029.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T09:21:28Z","timestamp":1555406488000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/71\/23\/2029\/5111038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,1]]},"references-count":24,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2014,12,1]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp140041","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2014,12,1]]},"published":{"date-parts":[[2014,12,1]]}}}